Biotechnology Value Trading Fund OS LP bought $14.0M of Kymera Therapeutics (KYMR)
Executed Jun 30 2025, disclosed Jul 1 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Jul 1 2025), the stock returned -2.1% (delay-adjusted); from the execution session (Jun 30 2025), -2.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Biotechnology Value Trading Fund OS LP (Director) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Kymera Therapeutics, Inc. (KYMR). Across 1 priced purchase filing, the average 21-session return was -2.1% from execution and -2.1% from disclosure (delay-adjusted; derived). The largest single filing was $14.0M of KYMR (317,167 sh across 3 lots, as filed), executed Jun 30 2025.
Healthcare · Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics th…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→